

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): April 22, 2022**

**Nkarta, Inc.**

(Exact name of Registrant as Specified in Its Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-39370**

(Commission File Number)

**47-4515206**  
(IRS Employer  
Identification No.)

**6000 Shoreline Court, Suite 102**  
**South San Francisco, CA**  
(Address of Principal Executive Offices)

**94080**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: (415) 582-4923**

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	NKTX	The Nasdaq Stock Market LLC (Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item. 7.01 Regulation FD Disclosure.**

On April 22, 2022, Nkarta, Inc. (the “Company”) issued a press release announcing that it will host a conference call on April 25, 2022 at 8:00 a.m. Eastern Time to discuss clinical data from its ongoing Phase 1 clinical trials assessing two lead clinical programs, NKX101 and NKX019. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be, or be deemed, incorporated by reference in any filings under the Securities Act of 1933, as amended (the “Securities Act”), unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or incorporates it by reference into a filing under the Securities Act or the Exchange Act.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit Number</b>	<b>Description</b>
99.1	<a href="#">Press Release issued on April 22, 2022.</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 22, 2022

Nkarta, Inc.

By: \_\_\_\_\_  
**/s/ Alicia Hager**  
**Alicia J. Hager, J.D., Ph.D.**  
**Chief Legal Officer**

---



## **Nkarta to Host Conference Call Highlighting Preliminary Clinical Data from Two Lead NK Cell Therapy Candidates**

*Call scheduled for Monday, April 25, 2022 8:00 a.m. ET*

*Clinical trial investigators to participate*

SOUTH SAN FRANCISCO, Calif., Apr. 22, 2022 -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will host a conference call on Monday, April 25, 2022 at 8:00 a.m. ET to review clinical data from its ongoing Phase 1 clinical trials assessing two lead clinical programs, NKX101 and NKX019. Leading investigators from the two clinical trials will join management for the discussion.

### **Conference Call and Webcast**

To access the conference call, please dial:

+1 (866) 518-6930 (domestic)

+1 (203) 518-9797 (international)

Conference ID "Nkarta"

A simultaneous webcast of the conference call and accompanying slides will be available on the Investors section of Nkarta's website, [www.nkartatx.com](http://www.nkartatx.com), and a replay will be archived on the website for approximately four weeks.

### **About NKX101**

NKX101, a wholly owned program of Nkarta, is a healthy donor-derived CAR-NK investigational therapy targeting NKG2D ligands on tumor cells. NKX101 is being investigated in an ongoing Phase 1 single-arm, multi-center, open label clinical trial that is designed to assess the safety and anti-tumor activity of NKX101 as a multi-dose, multi-cycle monotherapy in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes (MDS).

### **About NKX019**

NKX019, a wholly owned program of Nkarta, is a healthy donor-derived CAR-NK investigational therapy targeting CD19. NKX019 is being investigated in an ongoing Phase 1 single-arm, multi-center, open label clinical trial that is designed to assess the safety and anti-tumor activity of NKX019 as a multi-dose, multi-cycle monotherapy in patients with relapsed/refractory B cell malignancies.

### **About Nkarta**

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation

---

platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company's website at [www.nkartatx.com](http://www.nkartatx.com).

**Nkarta Media/Investor Contact:**

Greg Mann

Nkarta, Inc.

[gmann@nkartatx.com](mailto:gmann@nkartatx.com)

---

